PDT Partners LLC Trims Position in uniQure (NASDAQ:QURE)

PDT Partners LLC cut its position in uniQure (NASDAQ:QURE) by 58.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,199 shares of the biotechnology company’s stock after selling 81,802 shares during the period. PDT Partners LLC’s holdings in uniQure were worth $282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. abrdn plc increased its stake in shares of uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after acquiring an additional 109,740 shares during the last quarter. Privium Fund Management B.V. boosted its position in shares of uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after acquiring an additional 104,500 shares during the last quarter. FMR LLC boosted its position in shares of uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after acquiring an additional 346,274 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of uniQure by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock worth $1,367,000 after acquiring an additional 16,464 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research report on Wednesday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price objective on shares of uniQure in a research report on Wednesday, November 6th. Finally, Raymond James reiterated an “outperform” rating and set a $20.00 price objective on shares of uniQure in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, uniQure has a consensus rating of “Hold” and a consensus price target of $17.00.

uniQure Price Performance

uniQure stock opened at $6.41 on Wednesday. The firm has a 50-day moving average price of $6.05 and a 200-day moving average price of $6.02. The firm has a market capitalization of $312.42 million, a PE ratio of -1.29 and a beta of 0.89. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities research analysts forecast that uniQure will post -3.74 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.